SCHEMBL11077413

SCHEMBL11077413

Cc1cc(Cl)nc(CCl)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 4/20 0.39
CYP1A2 P05177 1/20 0.37
CASP1 P29466 1/20 0.37
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 1/20 0.34
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
NOD1 Q9Y239 1/20 0.33
JAK2 O60674 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
POLB P06746 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6631073 0.87 HTT (0.46) HTTSMN1; SMN2LMNAKMT2ACYP1A2
SCHEMBL2632758 0.84 HTT (0.44) HTTSMN1; SMN2LMNAKMT2ACYP1A2
SCHEMBL29826849 0.84 HTT (0.44) HTTSMN1; SMN2LMNAKMT2ACYP1A2
SCHEMBL22655940 0.82 HTT (0.43) HTTSMN1; SMN2LMNAKMT2ACYP1A2
SCHEMBL379234 0.82 HTT (0.34) HTTSMN1; SMN2KMT2AMAPK1NPC1
SCHEMBL1671889 0.80 HTT (0.42) HTTSMN1; SMN2LMNAKMT2ACYP1A2
SCHEMBL18614528 0.79 HTT (0.41) HTTSMN1; SMN2LMNAKMT2ACYP1A2
SCHEMBL13020600 0.79 HTT (0.41) HTTSMN1; SMN2LMNAKMT2ACYP1A2
SCHEMBL8901362 0.77 HTT (0.39) HTTSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL3281802 0.77 HTT (0.40) HTTSMN1; SMN2LMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-57091992-A None JP disclosed
CN-116354936-A Novel heterocyclic compounds useful as selective AURORA a inhibitors 北京加科思新药研发有限公司 2023-06-30 CN disclosed
US-20230128198-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-04-27 US disclosed
US-20230128198-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-04-27 US disclosed
US-20230128198-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-04-27 US disclosed
CN-114423751-B Novel heterocyclic compounds useful as selective AURORA a inhibitors 北京加科思新药研发有限公司 2023-04-21 CN disclosed
EP-4093736-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS Jacobio Pharmaceuticals Co., Ltd. (CN) 2022-11-30 EP disclosed
US-11384066-B1 Heterocyclic compounds useful as aurora a selective inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-07-12 US disclosed
US-11384066-B1 Heterocyclic compounds useful as aurora a selective inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-07-12 US disclosed
CN-114423751-A Novel heterocyclic compounds useful as selective AURORA a inhibitors 北京加科思新药研发有限公司 2022-04-29 CN disclosed
WO-2021147974-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-07-29 WO disclosed
EP-0015078-B1 ORGANO-PHOSPHORIC ESTERS, THEIR PRODUCTION AND USE AS PESTICIDES, AS WELL AS THE INTERMEDIATES THEREOF AND THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-07-04 EP disclosed
JP-S5791992-A PYRIMIDINE, ITS PREPARATION AND INSECTICIDE, ACARICIDE AND NEMATOCIDE CONTAINING THE SAME AS ACTIVE CONSTITUENT SUMITOMO CHEM CO LTD 1982-06-08 JP disclosed
US-4326058-A INSECTICIDE, ACARICIDE, AND NEMATOCIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1982-04-20 US disclosed
EP-0015078-A2 Organo-phosphoric esters, their production and use as pesticides, as well as the intermediates thereof and their production SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384066-B1 Heterocyclic compounds useful as aurora a selective inhibitors AURKA, AURKC, AURKB HTT 4306/4885SMN1; SMN2 4401/4885LMNA 1009/4885
US-20230128198-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS AURKA, AURKC, AURKB HTT 4284/4885SMN1; SMN2 4569/4885LMNA 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.